|
2025 Journal Article Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trialLewis, Katharine, Blombery, Piers, Sungala, Nagendra Prasad, Giri, Pratyush, Marconi, Tamara, Cochrane, Tara, Francis, Roslyn, Lee, Sze-Ting, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Keane, Colm, Hunter, Sally, Burgess, Melinda, Kannan, Sushmitha, Carlson, Julia, Walia, Mannu, Butcher, Belinda and Cheah, Chan (2025). Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial. Blood, 146 (Supplement 1), 1016-1016. doi: 10.1182/blood-2025-1016 |
|
2025 Conference Publication Divergent immune programs in EBV⁺ PCNSL: a multiomic study of AR-PCNSL and cns-PTLDBurgess, Melinda, Hawula, Zachary, Kempe, Sarah, Murigneux, Valentine, Swain, Fiona, Chowdhury, Rakin, Tuczko, Nella, Bradbury, Lucy, Antczak, Magdalena, Mehdi, Ahmed, Hawkes, Eliza, Wight, Joel, Gould, Clare, Gandhi, Maher, Jiang, Sizun, Maguire, Alanna and Keane, Colm (2025). Divergent immune programs in EBV⁺ PCNSL: a multiomic study of AR-PCNSL and cns-PTLD. 67th ASH Annual Meeting, Orlando, FL USA, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-457 |
|
2025 Conference Publication Multiomic dissection of immune-privileged DLBCL reveals divergent immune subtypes in testicular and primary central nervous system lymphomaBurgess, Melinda, Hawula, Zachary, Tuczko, Nella, Kempe, Sarah, Murigneux, Valentine, Swain, Fiona, Chowdhury, Rakin, Bradbury, Lucy, Antczak, Magdalena, Mehdi, Ahmed, Hawkes, Eliza, Wight, Joel, Henden, Andrea, Sheehy, Joshua, Gandhi, Maher, Jiang, Sizun and Keane, Colm (2025). Multiomic dissection of immune-privileged DLBCL reveals divergent immune subtypes in testicular and primary central nervous system lymphoma. 67th ASH Annual Meeting and Exposition, Orlando, FL, United States, 6-9 December 2025. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2025-147 |
|
2025 Journal Article Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphomaManos, Kate, Burgess, Melinda, Chong, Geoffrey, Lee, Sze-Ting, Smith, Charmaine, Renwick, William, Kempe, Sarah, Murigneux, Valentine, Chowdhury, Rakin, Blombery, Piers, Nelson, Niles, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Barraclough, Allison, Wight, Joel, Keane, Colm and Hawkes, Eliza (2025). Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma. Blood, 146 (Supplement 1), 3306-3306. doi: 10.1182/blood-2025-3306 |
|
2025 Conference Publication Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profilingHawula, Zachary, Tuczko, Nella, Burgess, Melinda, Bradbury, Lucy, Chowdhury, Rakin, Swain, Fiona, Hawkes, Eliza, Wight, Joel and Keane, Colm (2025). Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profiling. 67th ASH Annual Meeting, New Orleans, LA, United States, 12-15 December, 2025. New York, NY, United States: Elsevier. doi: 10.1182/blood-2025-149 |
|
2025 Journal Article Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated studySalvaris, Ross, Keane, Colm, Trotman, Judith, Sutherland, Antony, Waltham, Mark, Simpson, David, Gregory, Gareth P. and Opat, Stephen (2025). Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study. Blood, 146 (Supplement 1), 1926-1926. doi: 10.1182/blood-2025-1926 |
|
2025 Journal Article Characterizing the mechanistic role of TNF signaling via TNFR1 and TNFR2 on NK cell-mediated anti-tumor immunity 2859Alim, Louisa Frances, Lam, Pui Yeng, Keane, Colm and Souza-Fonseca-Guimaraes, Fernando (2025). Characterizing the mechanistic role of TNF signaling via TNFR1 and TNFR2 on NK cell-mediated anti-tumor immunity 2859. The Journal of Immunology, 214 (Supplement_1) vkaf283.730. doi: 10.1093/jimmun/vkaf283.730 |
|
2025 Journal Article T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trialHawkes, Eliza A., Palmer, Jodie, Khor, Richard, Lee, Sze Ting, Burgess, Melinda, Law, Soi C., Gandhi, Maher K., Chong, Geoffrey, Shortt, Jake, Chowdhury, Rakin, Swain, Fiona, Churilov, Leonid, MacManus, Michael M., Smith, Charmaine, Scott, Fiona Elizabeth, Martynchyk, Arina, Barraclough, Allison, Manos, Kate, Scott, Andrew M. and Keane, Colm (2025). T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial. Blood Advances, 9 (20), 5263-5273. doi: 10.1182/bloodadvances.2025016505 |
|
2025 Journal Article T cell immune profile changes predict durable response to nivolumab-rituximab in treatment naïve FLKoldej, Rachel M, Barraclough, Allison, Morgan, Huw, Lee, Sze Ting, Holzwart, Nicholas, Koshy, Minu, Smith, Charmaine, Chong, Geoff, Gilbertson, Michael, Keane, Colm, Lee, Denise, Churilov, Leonid, Ritchie, David S and Hawkes, Eliza A (2025). T cell immune profile changes predict durable response to nivolumab-rituximab in treatment naïve FL. Blood Neoplasia, 2 (4) 100168, 100168. doi: 10.1016/j.bneo.2025.100168 |
|
2025 Journal Article Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survivalWong, Kimberly S Q, Martynchyk, Arina, Krisnadi, Zoe, Swain, Fiona, Zargari, Ahmad, Cassidy, Luke, Mills, Georgia, Lim, Kenneth, Gervasi, Jeremy, Smallbone, Portia, Wang, Jenny, Slifirski, Olivia, Loh, Zoe, Cheah, Chan, Keane, Colm, Gregory, Gareth, Lasica, Masa, Chong, Geoffrey, Barraclough, Allison, Cochrane, Tara, Lee, Denise and Hawkes, Eliza (2025). Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival. JNCI: Journal of the National Cancer Institute, 117 (11) djaf174, 2240-2248. doi: 10.1093/jnci/djaf174 |
|
2025 Conference Publication Australian patients with relapsed or refractory diffuse large B‐cell lymphoma frequently fail eligibility criteria for landmark and registration clinical trialsGoodall, E., Palmer, J., Martynchyk, A., Waters, N., Swain, F., Marconi, T., Giang, T. B., Brennan, J., Gregory, G., Cheah, C., Keane, C. and Hawkes, E. (2025). Australian patients with relapsed or refractory diffuse large B‐cell lymphoma frequently fail eligibility criteria for landmark and registration clinical trials. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, 17 ‐ 21 June 2025. Wiley. doi: 10.1002/hon.70096_626 |
|
2025 Conference Publication Treatment of newly‐diagnosed follicular lymphoma with Rituximab, golcadomide +/‐ nivolumab‐ interim analysis of the phase II TOP‐FLOR studyMartynchyck, A., Chong, G., Barraclough, A., Ratnasingam, S., Marconi, T., Palmer, J. B., Keane, C., Lee, S. T. B., Scott, A. M., Romano, A., Churilov, L., Lee, D. and Hawkes, E. A. (2025). Treatment of newly‐diagnosed follicular lymphoma with Rituximab, golcadomide +/‐ nivolumab‐ interim analysis of the phase II TOP‐FLOR study. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, 17 ‐ 21 June 2025. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.70094_230 |
|
2025 Journal Article Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRIO’Shaughnessy, Jack, Martynchyk, Arina, Lee, Sze Ting, Chong, Geoff, Agrawal, Shivam, Tatarczuch, Maciej, Azryn, Nariza Alysa, Gregory, Gareth P., Churilov, Leonid, Wang, Michael, Keane, Colm and Hawkes, Eliza A. (2025). Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI. Neuro-Oncology Advances, 7 (1) vdaf090, vdaf090. doi: 10.1093/noajnl/vdaf090 |
|
2025 Journal Article Nivolumab and rituximab in treatment naive follicular lymphoma: the phase II '1st FLOR' studyBarraclough, Allison, Lee, Sze Ting, Burgess, Melinda, Churilov, Leonid, Chong, Geoffrey, Lee, Denise, Gilbertson, Michael, Fancourt, Tineke, Manos, Kate, Ritchie, David, Koldej, Rachel M, Scott, Andrew, Keane, Colm and Hawkes, Eliza A (2025). Nivolumab and rituximab in treatment naive follicular lymphoma: the phase II '1st FLOR' study. Blood Advances, 9 (6), 1432-1441. doi: 10.1182/bloodadvances.2024015487 |
|
2024 Journal Article Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMacManus, Michael P., Seymour, John F., Tsang, Hennes, Fisher, Richard, Keane, Colm, Sabdia, Muhammed B., Law, Soi C., Gunawardana, Jay, Nath, Karthik, Kazakoff, Stephen H., Marques-Piubelli, Mario L., Duenas, Daniela E., Green, Michael R., Roos, Daniel, O'Brien, Peter, McCann, Andrew, Tsang, Richard, Davis, Sidney, Christie, David, Cheah, Chan, Amanuel, Benhur, Cochrane, Tara, Butler, Jason, Johnston, Anna, Shanavas, Mohamed, Li, Li, Vajdic, Claire, Kridel, Robert, Shelton, Victoria ... Tobin, Joshua W. D. (2024). Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma. eBioMedicine, 110 105468, 1-13. doi: 10.1016/j.ebiom.2024.105468 |
|
2024 Journal Article Magrolimab plus rituximab with/without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphomaMaakaron, Joeseph, Asch, Adam S., Popplewell, Leslie, Collins, Graham P., Flinn, Ian W., Ghosh, Nilanjan, Keane, Colm, Ku, Matthew, Mehta, Amitkumar, Roschewski, Mark, Hacohen-Kleiman, Gal, Huo, Yanan, Zhang, Yi, Renard, Camille, Smith, Sonali M. and Advani, Ranjana H. (2024). Magrolimab plus rituximab with/without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 8 (22), 5864-5874. doi: 10.1182/bloodadvances.2024013338 |
|
2024 Journal Article Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationMcCulloch, Timothy R., Rossi, Gustavo R., Alim, Louisa, Lam, Pui Yeng, Wong, Joshua K. M., Coleborn, Elaina, Kumari, Snehlata, Keane, Colm, Kueh, Andrew J., Herold, Marco J., Wilhelm, Christoph, Knolle, Percy A., Kane, Lawrence, Wells, Timothy J. and Souza-Fonseca-Guimaraes, Fernando (2024). Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation. Nature Communications, 15 (1) 9871, 1-16. doi: 10.1038/s41467-024-54232-y |
|
2024 Conference Publication Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in ProgressTatarczuch, Maciej, Keane, Colm, Brown, Christina, Giri, Pratyush, Cull, Gavin, Lasica, Masa, Shuttleworth, Charles, Wight, Joel, Tabesh, Marjan, Butcher, Belinda E., Lee, Sze Ting, Hawkes, Eliza A. and Gregory, Gareth P. (2024). Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-200410 |
|
2024 Conference Publication Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell LymphomaLewis, Katharine L., Giri, Pratyush, Marconi, Tamara, Blombery, Piers, Keane, Colm, Sungala, Nagendra Prasad, Cochrane, Tara, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Francis, Roslyn, Walia, Mannu, Carlson, Julia, Butcher, Belinda E. and Cheah, Chan Y. (2024). Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204317 |
|
2024 Conference Publication Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at RelapseSwain, Fiona, Burgess, Melinda, Kempe, Sarah, Sabdia, Muhammed B., Henden, Andrea S., Wight, Joel, Hawkes, Eliza A., Mutsando, Howard, Talaulikar, Dipti, Merida de Long, Lilia, Birch, Simone, Wyche, Penelope, Hawula, Zachary, Chowdhury, Rakin, Gandhi, Maher K. and Keane, Colm (2024). Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-199352 |
